UroGen Pharma (NASDAQ:URGN) Receives “Buy” Rating from HC Wainwright

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Thursday, MarketBeat Ratings reports. They currently have a $54.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 293.30% from the stock’s current price.

Separately, Oppenheimer reduced their target price on shares of UroGen Pharma from $35.00 to $34.00 and set an “outperform” rating for the company in a research note on Friday, March 15th.

UroGen Pharma Price Performance

NASDAQ URGN opened at $13.73 on Thursday. UroGen Pharma has a 1 year low of $8.69 and a 1 year high of $24.13. The firm has a market cap of $322.02 million, a price-to-earnings ratio of -3.68 and a beta of 1.07. The company has a fifty day moving average price of $16.19 and a 200-day moving average price of $14.59.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, March 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.05). The firm had revenue of $23.53 million for the quarter, compared to analysts’ expectations of $22.30 million. On average, research analysts anticipate that UroGen Pharma will post -3.59 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Mark Schoenberg sold 3,789 shares of the business’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total value of $59,638.86. Following the transaction, the insider now directly owns 149,423 shares of the company’s stock, valued at approximately $2,351,918.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, General Counsel Jason Drew Smith sold 4,993 shares of the business’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total value of $78,589.82. Following the transaction, the general counsel now directly owns 18,824 shares of the company’s stock, valued at approximately $296,289.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Schoenberg sold 3,789 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $15.74, for a total transaction of $59,638.86. Following the completion of the transaction, the insider now directly owns 149,423 shares in the company, valued at $2,351,918.02. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,782 shares of company stock valued at $306,829. 11.13% of the stock is owned by insiders.

Institutional Investors Weigh In On UroGen Pharma

Institutional investors have recently added to or reduced their stakes in the business. Lazard Asset Management LLC purchased a new stake in UroGen Pharma during the fourth quarter valued at about $27,000. Acadian Asset Management LLC purchased a new stake in UroGen Pharma during the first quarter valued at about $42,000. Legal & General Group Plc lifted its holdings in UroGen Pharma by 34.6% during the fourth quarter. Legal & General Group Plc now owns 2,868 shares of the company’s stock valued at $43,000 after purchasing an additional 738 shares during the last quarter. BNP Paribas Arbitrage SNC lifted its holdings in UroGen Pharma by 2,782.5% during the second quarter. BNP Paribas Arbitrage SNC now owns 5,102 shares of the company’s stock valued at $53,000 after purchasing an additional 4,925 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new stake in UroGen Pharma during the third quarter valued at about $53,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.